Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment

Ads

You May Also Like

U.S. IND Becomes Active for BGB-A317, an Anti-PD-1 Monoclonal Antibody

BEIJING, Jan. 08, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused ...

aTyr Pharma to Present at Two Upcoming Investor Conferences in September

SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics ...